Gubra A/S Stock
Gubra A/S Stock price
Key metrics
Is Gubra A/S a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 7,032 stocks worldwide.
Gubra A/S Stock Analysis
Analyst Opinions
12 Analysts have issued a Gubra A/S forecast:
Analyst Opinions
12 Analysts have issued a Gubra A/S forecast:
Financial data from Gubra A/S
| Mar '25 |
+/-
%
|
||
| Revenue | 323 323 |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | 7.49 7.49 |
-
|
| Net Profit | 21 21 |
-
|
|
In millions DKK.
Don't miss a Thing! We will send you all news about Gubra A/S directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Gubra ApS operates as biotechnology company. It engages in the business of pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. The company operates through two business segments: CRO Services and Discovery & Partnerships. The CRO Services segment provides specialized pre-clinical contract research and development services for the pharmaceutical and biotechnology industry. The Discovery & Partnerships segment involves in discovery, design and development of peptide-based drug candidates with the aim of entering partnerships with pharmaceutical or biotechnology companies. Gubra was founded by Jacob Jelsing and Niels Vrang in 2008 and is headquartered in Horsholm, Denmark.
| Head office | Denmark |
| CEO | Mr. Blou |
| Employees | 235 |
| Founded | 2008 |
| Website | www.gubra.dk |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
